Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of the study is to confirm if BACTEK-R (MV130) provides clinical benefit in subject with mild pneumonia (CURB-65≤2) by COVID-19 admitted to the Hospital.
Description: Number of subjects presenting a improvement in their clinical condition from day 1 to 14 that lead their hospital discharged. Based on the measure of the secondary outcomes.
Measure: Clinical recovery Time: 2 weeksDescription: Number of subjects presenting a worsening in their clinical condition from day 1 to 14 that leads to their admission to the intensive care unit or their death. Based on the measure of the secondary outcomes.
Measure: Clinical worsening Time: 2 weeksDescription: Symptom (fever, cough, dyspnea, myalgia, diarrhea and so on) will be daily record and classified as mild, moderate, severe.
Measure: Clinical severity Time: 2 weeksDescription: Time of reduction or disappearance of the symptoms
Measure: Time to symptoms remission Time: 2 weeksDescription: Record of all the medication administered to the subject
Measure: Medication Use Time: 2 weeksDescription: Time from the subject's admission to the coronavirus unit until discharge
Measure: Hospitalization time Time: 2 weeksDescription: Blood routine test will be carried out days 1 and 7
Measure: Blood routine test Time: Days 1 and 7Description: Heart rate will be followed everyday during time frame
Measure: Heart rate Time: 2 weeksDescription: Blood pressure will be followed everyday during time frame
Measure: Blood pressure Time: 2 weeksDescription: Cardiac auscultation will be recorded everyday during time frame
Measure: Cardiac auscultation Time: 2 weeksDescription: Blood oxygen saturation will be followed everyday during time frame
Measure: Oxygen saturation Time: 2 weeksDescription: Adverse events during treatment
Measure: Adverse events Time: 2 weeks